AQST Aquestive Therapeutics

Aquestive Therapeutics to Announce Third Quarter Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET

Aquestive Therapeutics to Announce Third Quarter Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET
EN
14/10/2020

Underlying

AQSTAquestive Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aquestive Therapeutics

 PRESS RELEASE
Free
AQST Aquestive Thera...

Aquestive Therapeutics to Participate in Upcoming March Investor Confe...

Aquestive Therapeutics to Participate in Upcoming March Investor Conferences WARREN, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in four upcoming investor conferences in March as follows: TD Cowen 46th Annual Health Care Conference: Management will be available for 1x1 meetings on Tuesday, March 3rdLeerink Partner...

February 25, 2026 1 EN
 PRESS RELEASE
Free
AQST Aquestive Thera...

Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results...

Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET WARREN, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the fourth quarter ended December 31, 2025 and provide an update on recent developments in its business afte...

February 24, 2026 1 EN
 PRESS RELEASE
Free
AQST Aquestive Thera...

Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healt...

Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference WARREN, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in the upcoming Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, which is a virtual event. The Aquestive team will be presenting on ...

February 23, 2026 1 EN
 PRESS RELEASE
Free
AQST Aquestive Thera...

Aquestive Therapeutics to Present New Clinical Data on Anaphylm™ (dibu...

Aquestive Therapeutics to Present New Clinical Data on Anaphylm™ (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting Anaphylm™ (dibutepinephrine) sublingual film achieved clinically relevant epinephrine plasma concentrations without diastolic blood pressure dip WARREN, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that multiple poster prese...

February 20, 2026 1 EN
 PRESS RELEASE
Free
AQST Aquestive Thera...

Aquestive Therapeutics Appoints Internationally Recognized Allergist D...

Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer Board-certified allergist and leading food allergy and anaphylaxis researcher joins Aquestive to support Anaphylm™ (dibutepinephrine) sublingual film NDA resubmission and pipeline WARREN, N.J., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appo...

February 18, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch